EGFR and neoplasm: This study aimed to increase the selectivity of anti-EGFR ITs for cells with a higher expression of EGFR compared to cells with low EGFR expression to minimize the risk of on-target/off-tumor toxicity and to expand the therapeutic window of EGFR targeting ITs.